全文获取类型
收费全文 | 1324745篇 |
免费 | 101936篇 |
国内免费 | 4219篇 |
专业分类
耳鼻咽喉 | 16787篇 |
儿科学 | 43455篇 |
妇产科学 | 36365篇 |
基础医学 | 196186篇 |
口腔科学 | 35873篇 |
临床医学 | 128814篇 |
内科学 | 255495篇 |
皮肤病学 | 26347篇 |
神经病学 | 110982篇 |
特种医学 | 48113篇 |
外国民族医学 | 366篇 |
外科学 | 183461篇 |
综合类 | 28738篇 |
现状与发展 | 1篇 |
一般理论 | 460篇 |
预防医学 | 113293篇 |
眼科学 | 28927篇 |
药学 | 98546篇 |
6篇 | |
中国医学 | 3096篇 |
肿瘤学 | 75589篇 |
出版年
2019年 | 11627篇 |
2018年 | 16303篇 |
2017年 | 12284篇 |
2016年 | 13244篇 |
2015年 | 15190篇 |
2014年 | 20799篇 |
2013年 | 32048篇 |
2012年 | 44232篇 |
2011年 | 46885篇 |
2010年 | 27068篇 |
2009年 | 24921篇 |
2008年 | 42719篇 |
2007年 | 45059篇 |
2006年 | 45170篇 |
2005年 | 43587篇 |
2004年 | 41547篇 |
2003年 | 39411篇 |
2002年 | 38217篇 |
2001年 | 60731篇 |
2000年 | 62353篇 |
1999年 | 51921篇 |
1998年 | 13684篇 |
1997年 | 12261篇 |
1996年 | 12158篇 |
1995年 | 12354篇 |
1994年 | 11568篇 |
1993年 | 10828篇 |
1992年 | 41479篇 |
1991年 | 40745篇 |
1990年 | 39424篇 |
1989年 | 37312篇 |
1988年 | 34541篇 |
1987年 | 33670篇 |
1986年 | 32118篇 |
1985年 | 30621篇 |
1984年 | 22991篇 |
1983年 | 19525篇 |
1982年 | 11690篇 |
1981年 | 10221篇 |
1979年 | 20759篇 |
1978年 | 14770篇 |
1977年 | 12016篇 |
1976年 | 11835篇 |
1975年 | 12082篇 |
1974年 | 14774篇 |
1973年 | 14452篇 |
1972年 | 13350篇 |
1971年 | 12410篇 |
1970年 | 11473篇 |
1969年 | 10404篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Matthias Knefel PhD Elisabeth L. Zeilinger PhD Simone Lubowitzki PhD Katharina Krammer MSc Matthias Unseld MD Rupert Bartsch MD Thorsten Fuereder MD Ulrich Jäger MD Barbara Kiesewetter MD Maria Krauth MD Markus Raderer MD Philipp B. Staber MD Peter Valent MD Alexander Gaiger MD 《Cancer》2023,129(21):3466-3475
Background
Survival in cancer patients is associated with a multitude of biological, social, and psychological factors. Although it is well established that all these factors add to overall mortality, it is not well understood how the predictive power of these parameters changes in a comprehensive model and over time.Methods
Patients who attended the authors’ outpatient clinic were invited to participate. The authors followed 5180 mixed cancer patients (51.1% female; mean age, 59.1 years [SD = 13.8]) for up to 16 years and analyzed biological (age, sex, cancer site, anemia), psychological (anxiety, depression), and social variables (marital status, education, employment status) potentially predicting overall survival in a Cox proportional hazards model.Results
The median survival time for the entire sample was 4.3 years (95% confidence interval, 4.0–4.7). The overall survival probabilities for 1 and 10 years were 76.8% and 38.0%, respectively. Following an empirical approach, the authors split the time interval into five periods: acute, subacute, short-term, medium-term, and long-term. A complex pattern of variables predicted overall survival differently in the five periods. Biological parameters were important throughout most of the time, social parameters were either time-independent predictors or tended to be more important in the longer term. Of the psychological parameters, only depression was a significant predictor and lost its predictive power in the long-term.Conclusions
The findings of this study allow the development of comprehensive patient-specific models of risk and resilience factors addressing biopsychosocial needs of cancer patients, paving the way for a personalized treatment plan that goes beyond biomedical cancer care. 相似文献102.
103.
104.
105.
106.
107.
Andrea Ferrari MD Daniel Orbach MD Michela Casanova MD Max M. van Noesel MD Pablo Berlanga MD Bernadette Brennan MD Nadege Corradini MD Reineke A. Schoot MD Gema L. Ramirez-Villar MD Lisa Lyngsie Hjalgrim MD Rita Alaggio MD Gabriela Guillen Burrieza MD Akmal Safwat MD Alison L. Cameron MD Rick R. van Rijn MD Veronique Minard-Colin MD Ilaria Zanetti BSc Gianni Bisogno MD Julia C. Chisholm MD Johannes H. M. Merks MD 《Cancer》2023,129(16):2542-2552
Background
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined.Methods
This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered.Results
The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2–111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6–25.7) and 34.9% (95% CI, 22.7–47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered.Conclusions
The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge.Plain Language Summary
- Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors.
- Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases.
- This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.
108.
109.